To increase the 5-year survival rate from 12.8% to 50% in the next 10 years through early detection and prevention of pancreatic cancer.
ClearNote Health Joins the Pancreatic Cancer Early Detection (PRECEDE) Consortium in New Partnership to Reduce Cancer Mortality
PRECEDE at the
John R. Lewis Legacy Institute
Research Spotlight:
Cure Prize Team Leader
Andrew Lowy, MD, PhD
Our Mission
Our Goal
To raise funds to support The Pancreatic Cancer Early Detection (PRECEDE) Consortium.
PRECEDE is an international, multi-institutional collaborative consortium of world renowned experts in pancreatic cancer. The goal of PRECEDE to increase survival for patients by improving early detection, screening, risk modeling and prevention for those with a heritable risk for pancreatic cancer, through a novel model of collaboration and data sharing. With over 35 leading academic medical centers across the globe, PRECEDE has assembled the largest high-risk patient cohort, with biospecimen collection and longitudinal clinical data.
TrovaNOW proceeds go towards collaborative research to detect pancreatic cancers earlier, saving thousands of lives from the world’s deadliest cancer. This revolutionary effort is for early detection, screening and prevention for pancreatic cancer.
Pancreatic cancer is one of the world’s deadliest cancers, with a 5-year survival rate of just 12.8%.
In the United States it’s the 3rd most deadly cancer, and about 70% of patients die within 1 year of diagnosis.
Globally, pancreatic cancer is the 7th leading cause of death.
Both the incidence and mortality of pancreatic cancer are still increasing, while deaths from other cancers are declining. Pancreatic cancer is projected to become the 2nd leading cause of cancer-related deaths in the U.S. by 2030. This is why pancreatic cancer awareness is so important.
